a day ago
- Business
- Wall Street Journal
Sanofi to Buy Vaccine Developer Vicebio for Up to $1.6 Billion
Sanofi SAN -0.99%decrease; red down pointing triangle said it agreed to buy U.K. vaccine developer Vicebio for up to $1.6 billion, adding vaccine candidates for respiratory syncytial virus and human metapneumovirus to its pipeline.
The French pharmaceutical group said Tuesday that the deal for privately-held Vicebio includes an upfront payment of $1.15 billion and potential payments of up to $450 million subject to achieving certain development and regulatory milestones.
